Commensals upon us
Antibacterial drug discovery—Then, now and the genomics future
Practical applications and feasibility of efflux pump inhibitors in the clinic—A vision for applied use
Natural products — The future scaffolds for novel antibiotics?
Understanding the longevity of the β-lactam antibiotics and of antibiotic/β-lactamase inhibitor combinations
Dihydrofolate reductase inhibitors as antibacterial agents
Efflux systems in bacterial pathogens: An opportunity for therapeutic intervention? An industry view
Targeting the forgotten transglycosylases
Glycopeptides: Update on an old successful antibiotic class
The historical delivery of antibiotics from microbial natural products—Can history repeat?
Unmet medical needs in antibacterial therapy
Does the cell wall of bacteria remain a viable source of targets for novel antibiotics?
Empirical antibacterial drug discovery—Foundation in natural products
Structure-based drug design meets the ribosome
Use of constraint-based modeling for the prediction and validation of antimicrobial targets
Surveillance uncovers the smoking gun for resistance emergence
The evolution of peptide deformylase as a target: Contribution of biochemistry, genetics and genomics
Crystallizing new approaches for antimicrobial drug discovery
The role of pharmacodynamic research in the assessment and development of new antibacterial drugs
Use of genomics to select antibacterial targets
The forgotten Gram-negative bacilli: What genetic determinants are telling us about the spread of antibiotic resistance
Redefining penems
When will the genomics investment pay off for antibacterial discovery?